What are the manufacturers of Nilotinib?

Nilotinib (Nilotinib) was developed by Novartis. It was developed based on the structure of the Abl-imatinib complex to solve the problems of imatinib intolerance and resistance. Nilotinib is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+CML-CP in children.

Chronic myeloid leukemia (CML) is a type of cancer in which the body produces cancerous white blood cells. Nearly all people with CML have an abnormality called the Philadelphia chromosome, which produces a protein called BCR-ABL. In newly diagnosed CML patients, major molecular response (MMR at 12 cycles, BCR ABL/ABL <=0.1% International standard [IS] rate was 60.0%, with 15 patients achieving MMR. Among patients who were resistant or intolerant to prior therapy, including imatinib, the MMR rate at 12 cycles was 40.9%, with 18 patients at MMR. MR status. In patients with newly diagnosed CML, the cumulative MMR rate by cycle 12 was 64.0%. In patients with resistance or intolerance to prior therapy, including imatinib, the cumulative MMR rate at cycle 12 was 47.7%.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 tablets per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.